Multiscale mapping of transcriptomic signatures for cardiotoxic drugs

Author:

Hansen JensORCID,Xiong YuguangORCID,Dhanan Priyanka,Hu Bin,Yadaw Arjun S.ORCID,Jayaraman Gomathi,Tolentino Rosa,Chen Yibang,Beaumont Kristin G.ORCID,Sebra RobertORCID,Vidovic DusicaORCID,Schürer Stephan C.,Goldfarb Joseph,Gallo James,Birtwistle Marc R.ORCID,Sobie Eric A.ORCID,Azeloglu Evren U.ORCID,Berger SethORCID,Chan AngelORCID,Schaniel ChristophORCID,Dubois Nicole C.,Iyengar RaviORCID

Abstract

AbstractDrug-induced gene expression profiles can identify potential mechanisms of toxicity. We focused on obtaining signatures for cardiotoxicity of FDA-approved tyrosine kinase inhibitors (TKIs) in human induced pluripotent stem cell-derived cardiomyocytes. Using bulk transcriptomics profiles, we applied singular value decomposition to identify drug-selective patterns in cell lines obtained from multiple healthy human subjects. Cellular pathways affected by highly cardiotoxic TKIs include energy metabolism, contractile, and extracellular matrix dynamics. Projecting these pathways to single cell expression profiles indicates that TKI responses can be evoked in both cardiomyocytes and fibroblasts. Whole genome sequences of the cell lines, using outlier responses enabled us to correctly reidentify a genomic variant associated with anthracycline cardiotoxicity and predict genomic variants potentially associated with TKI cardiotoxicity. We conclude that mRNA expression profiles when integrated with publicly available genomic, pathway, and single cell transcriptomic datasets, provide multiscale predictive understanding of cardiotoxicity for drug development and patient stratification.One sentence summaryGenes, pathways, and cell types of the human heart associated with antineoplastic drug cardiotoxicity.

Publisher

Cold Spring Harbor Laboratory

Reference93 articles.

1. The incidence and nature of in-hospital adverse events: a systematic review

2. Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective;JACC Basic Transl Sci,2018

3. Improving the drug development process by reducing the impact of adverse events: the case of cataracts considered;Drug Discov Today,2016

4. Dorato, M. A. & Buckley, L. A. Toxicology in the drug discovery and development process. Curr Protoc Pharmacol Chapter 10, Unit10 13 (2006). https://doi.org:10.1002/0471141755.ph1003s32

5. Network analysis of FDA approved drugs and their targets

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3